4d Pharma (DDDD)

Company name:4d Pharma Plc
EPIC:DDDDTrading Currency:GBX
Market Sector:ASM7ISIN:GB00BJL5BR07
Market Segment:AMSMShare Type:DE
WWW Address:http://www.4dpharmaplc.com/Description:ORD 0.25P
 Price Price Change [%] Bid Ask Open High Low Volume
 16.36 images.advfn.com/imagesnew/2/us/dot 0.0 [0.00] - - - - - -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 29.50 180.34 0.07 -22.80 - - - 96.00 - 13.60

4d Pharma Key Figures

Key Figures
(at previous day's close)
Market Cap.29.50m
Shares In Issue180.34m
Prev. Close16.36
PE Ratio- 
Dividend Yield-%
EPS - basic-22.80p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-12.57p
Return On Equity (ROE)-92.43%
Operating Margin-5,682.77%
PEG Factor- 
EPS Growth Rate37.96%
Dividends PS Growth Rate-%
Net Debt-1.32m
Gross Gearing21.04%
Quick Assets16.61m
Net Working Capital10.45m
Intangibles / Fixed Assets75.73%
Turnover PS0.30p
Pre-Tax Profit PS-16.83p
Retained Profit PS-14.34p
Cash PS4.87p
Net Cash PS1.29p
Net Tangible Asset Value PS *7.73p
Net Asset Value PS15.51p
Spread- (-%) 

4d Pharma Balance Sheet

%1$s Balance Sheet

Share Price Performance

Sorry No Data Available

Share Price Chart (5 years)

Share Price Chart (5 years)

4d Pharma Historic Returns

Sorry No Data Available

4d Pharma Key Management Ratios


4d Pharma Investment Ratios

%1$s Investment Ratios
(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 0.89 
Tobin's Q Ratio (excl. intangibles)1.55 
Dividend Yield-%
Market-to-Book Ratio1.05 
Price-to-Pre-Tax Profit PS-0.97 
Price-to-Retained Profit PS-1.14 
Price-to-Cash Flow PS-1.30 
Price-to-Sales PS55.25 
Price-to-Net Tangible Asset Value PS2.12 
Price-to-Cash PS3.36 
Net Working Capital PS5.79 
Price Pct to Working Capital PS2.82%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

4d Pharma Financial Ratios

%1$s Financial Ratios
(Leverage Ratios)
Debt Ratio3.45%
Debt-to-Equity Ratio0.04 
Debt-to-Equity Ratio (excl. Intgbl)0.07 
Debt-to-Equity Market Value0.03 
Net Gearing-3.74%
Net Gearing (excl. Intangibles)-6.19%
Gross Gearing21.04%
Gross Gearing (excl. Intangibles)34.82%
Gearing Under 1 Year18.22%
Gearing Under 1 Year (excl. Intgbl)30.16%
(Liquidity Ratios)
Net Working Capital to Total Assets29.50%
Current Ratio2.62 
Quick Ratio (Acid Test)2.57 
Liquidity Ratio1.36 
Cash & Equiv/Current Assets51.92%
(Solvency Ratios)
Enterprise Value21.73m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.25 
Total Debt/Sales13.95 
Total Debt/Pre-Tax Profit-0.25 
Total Debt7.45m
Total Debt/Net Current Assets0.71%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-14.26%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs5 
Beta coefficients
Beta (60-Mnth)Beta (36-Mnth)

4d Pharma Operating Ratios

%1$s Operating Ratios
(Profitability Ratios)
Return On Capital Employed (ROCE)-104.75%
Return On Assets (ROA)-78.31%
Net Profit Margin-4,841.39%
Assets Turnover0.02 
Return On Equity (ROE)-92.43%
Return On Investment (ROI)-96.97%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-4,841.39%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.02 
Fixed Assets Turnover0.03 
Current Assets Turnover0.04 
Net Working Capital Turnover 
Inventory Turnover2.18 
(Other Operating Ratios)
Total Assets-to-Sales61.83 
Debt Collection Period5,216.63Days

4d Pharma Dividends

Sorry No Data Available

4d Pharma Fundamentals

Profit and Loss Account
 31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (GBP)
pre tax profit-23.99--28.44--29.43--30.35-m
attributable profit-19.39--24.29--23.69--25.85-m
retained profit-19.39--24.29--23.69--25.85-m
eps - basic (p)-31.41 -36.17 -36.75 -22.80 
eps - diluted (p)-31.41 -36.17 -36.75 -22.80 
dividends per share- - - - 

4d Pharma Balance Sheet

Balance Sheet
 31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (GBP)
 31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (GBP)
fixed assets fixed assets5.216.70%4.879.25%5.1616.86%4.4912.69%m
intangibles intangibles14.6718.88%14.4527.46%13.9945.70%14.0339.60%m
fixed investments fixed investments38.1349.05%--%--%--%m
current assets - other current assets - other--%--%--%--%m
stocks stocks0.250.33%0.290.55%0.200.65%0.290.82%m
debtors debtors7.609.78%16.9532.23%7.4324.27%7.8422.12%m
cash & securities cash & securities11.8715.26%16.0530.52%3.8412.53%8.7824.77%m
creditors - short creditors - short4.986.41%5.189.84%6.2620.45%6.4518.22%m
creditors - long creditors - long2.973.82%1.673.17%2.016.56%1.002.82%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves69.7989.77%45.7686.99%22.3472.99%27.9778.96%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

4d Pharma Cash Flow Statement

%1$s Cash Flow Statement
31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (GBP)
Operating CF-17.19-22.94-21.56-22.67m
Pre-Financing CF-16.784.20-11.84-22.85m
Retained CF-16.804.19-12.224.94m

4d Pharma Brokers

Broker infomation is not available for this class of share.
Your Recent History
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:ca D:20220815 09:42:21